Atyr PHARMA INC (NASDAQ:ATYR) Short Interest Up 8.5% in January

Atyr PHARMA INC (NASDAQ:ATYR) saw a significant growth in short interest in the month of January. As of January 31st, there was short interest totalling 3,820,000 shares, a growth of 8.5% from the January 15th total of 3,520,000 shares. Based on an average daily volume of 820,000 shares, the days-to-cover ratio is currently 4.7 days. Approximately 4.7% of the shares of the company are sold short.

Analyst Ratings Changes

ATYR has been the topic of a number of analyst reports. Cantor Fitzgerald assumed coverage on Atyr PHARMA in a research report on Monday, January 6th. They set an “overweight” rating on the stock. HC Wainwright reissued a “buy” rating and set a $35.00 target price on shares of Atyr PHARMA in a report on Tuesday, December 10th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, Atyr PHARMA has a consensus rating of “Buy” and an average price target of $19.25.

Atyr PHARMA Trading Down 5.0 %

ATYR traded down $0.18 during trading on Friday, hitting $3.41. 1,056,479 shares of the stock traded hands, compared to its average volume of 722,426. The business has a 50 day moving average price of $3.55 and a 200 day moving average price of $2.82. The company has a quick ratio of 5.41, a current ratio of 5.41 and a debt-to-equity ratio of 0.02. Atyr PHARMA has a twelve month low of $1.42 and a twelve month high of $4.22.

Hedge Funds Weigh In On Atyr PHARMA

A number of institutional investors have recently modified their holdings of ATYR. Jane Street Group LLC bought a new position in Atyr PHARMA in the fourth quarter valued at about $720,000. Schonfeld Strategic Advisors LLC acquired a new stake in shares of Atyr PHARMA in the 4th quarter valued at approximately $230,000. Northern Trust Corp bought a new stake in shares of Atyr PHARMA during the 4th quarter valued at approximately $661,000. Oxford Asset Management LLP acquired a new position in Atyr PHARMA during the 4th quarter worth approximately $115,000. Finally, Boothbay Fund Management LLC bought a new position in Atyr PHARMA in the 4th quarter valued at approximately $53,000. Institutional investors and hedge funds own 61.72% of the company’s stock.

Atyr PHARMA Company Profile

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.